AI/ML
Alloy Insights — AI/ML Built Into the Alloy Discovery & Development Engine
AI/ML is built directly into the infrastructure of our platform, accelerating the scientists and engineers who run it.
Trained on one of the industry’s largest in-house experimental datasets, our models improve predictions and shorten cycles. By unifying software with our global wet-lab engine, we enable teams to get from an idea to human data for less than $10M.
Our Capabilities
Integrated AI for real
biological outcomes
Alloy Therapeutics unites proprietary in vivo discovery platforms with state-of-the-art AI/ML to deliver more predictable, more potent, and more developable therapeutic antibodies.
Our integrated workflows don’t just screen for what exists—they actively design what should exist, pairing in silico prediction with rapid wet-lab validation to move programs from idea to insight with unprecedented speed and precision.
Deep Repertoire Intelligence
We go beyond traditional random screening to computationally analyze immune responses from ATX-Gx™ mice, mining the full richness of the repertoire.
SmartSelect™
Advanced NGS informatics and proprietary algorithms surface diverse, epitope-spanning clones that often remain invisible to standard approaches.
Liability Detection
Advanced NGS informatics and proprietary algorithms surface diverse, epitope-spanning clones that often remain invisible to standard approaches.
Repertoire Visualization
Advanced NGS informatics and proprietary algorithms surface diverse, epitope-spanning clones that often remain invisible to standard approaches.
Generative Design & High-Precision Optimization
Our AI/ML toolkit includes protein language models, diffusion models, Bayesian optimization engines, and guided mutational strategies.
ACE: AI-guided Clonotype Expansion
AI-guided Clonotype Expansion and Iterative Design generate and prioritize libraries tailored to affinity, specificity, or function.
Affinity Engineering
Advanced NGS informatics and proprietary algorithms surface diverse, epitope-spanning clones that often remain invisible to standard approaches.
Targeted Property Tuning
Advanced NGS informatics and proprietary algorithms surface diverse, epitope-spanning clones that often remain invisible to standard approaches.
Majority of round 2 leads show improved affinity (KD<500 pM) and reduced hydrophobicity.
The Power of Integration: AI × mAbForge™
Alloy’s AI becomes most powerful when paired with mAbForge™, our high-throughput expression and characterization engine.
A Closed Design–Build–Test Loop
Experimental data continuously trains and refines our models. Learnings compound quickly—binding data in 2–3 weeks.
Hard-to-Drug Targets
Advanced NGS informatics and proprietary algorithms surface diverse, epitope-spanning clones that often remain invisible to standard approaches.
End-to-End Platform
Advanced NGS informatics and proprietary algorithms surface diverse, epitope-spanning clones that often remain invisible to standard approaches.
- Rapid expression and testing ~180 genAI designed variants per round
- After 2 rounds, antibodies affinities had improved to < 100 pM and functional potency was better than clinical comparators
Predictive Developability
We help teams fail fast and succeed faster by predicting manufacturability and formulation outcomes before wet-lab work begins.
Computational Developability Scoring
Models assess viscosity, hydrophobicity, aggregation risk, and other biophysical parameters early in design.
Structural Modeling at Scale
Advanced NGS informatics and proprietary algorithms surface diverse, epitope-spanning clones that often remain invisible to standard approaches.
Get the full picture
Read a case study on our AI/ML powered antibody optimization
Discover how Alloy’s AI/ML platform integrates with our discovery ecosystem—from repertoire mining and generative design to predictive developability and mAbForge™ validation.
Partner with Alloy
Where AI innovation and in vivo biology reinforce each other, better medicines emerge. Alloy partners with teams across biotech, pharma, and academia to accelerate antibody discovery programs and deliver high-quality therapeutic candidates with confidence.
